Searles Andrew
Calvary Mater Newcastle, University of Newcastle, Newcastle, NSW 2310.
Aust Health Rev. 2009 May;33(2):186-91. doi: 10.1071/ah090186.
In January 2005 Australia implemented the Australia-United States Free Trade Agreement (AUSFTA). The agreement had placed domestic health policy and the Pharmaceutical Benefits Scheme (PBS) in particular, on the trade negotiating table. At the time Australians were told the PBS would not be undermined, but why was it included in a trade agreement? This article argues that recent reforms to the PBS partially delivered on an issue that the US has compelled its trade negotiators to ensure since 2002: the elimination of reference pricing. In Australia, reference pricing, as used by the PBS, had been credited with obtaining money when buying new medicines.
2005年1月,澳大利亚实施了《澳美自由贸易协定》(AUSFTA)。该协定将国内卫生政策,尤其是药品福利计划(PBS)置于贸易谈判桌上。当时,澳大利亚人被告知药品福利计划不会受到损害,但为何它会被纳入一项贸易协定呢?本文认为,药品福利计划最近的改革部分解决了自2002年以来美国一直迫使其贸易谈判代表确保的一个问题:取消参考定价。在澳大利亚,药品福利计划所采用的参考定价曾被认为在购买新药时节省了资金。